Category: fda

FDA Looks Into Dental Device After KHN-CBS News Investigation of Patient Harm

The FDA’s interest in the AGGA dental device follows a KHN-CBS News investigation, according to a former agency official.

Despite Pharma Claims, Illicit Drug Shipments to US Aren’t Full of Opioids. It’s Generic Viagra.

The FDA has long blocked the importation of cheap medicine, agreeing with pharmaceutical manufacturers that it opens the door to opioids. The agency’s own data shows that rarely happens.

March Medicaid Madness

With Medicare and Social Security apparently off the table for federal budget cuts, the focus has turned to Medicaid, the federal-state health program for those with low incomes. President Joe Biden has made it clear he wants to protect the program, along with the Affordable Care Act, but Republicans will likely propose cuts to both […]

One Texas Judge Will Decide Fate of Abortion Pill Used by Millions of American Women

“What happens in Texas doesn’t stay in Texas,” warns an abortion rights advocate bracing for a district judge’s ruling on whether the abortion pill mifepristone was properly authorized by the FDA. His decision could force the medication off the U.S. market.

A Bitter Battle Over the ‘Orphan Drug’ Program Leaves Patients’ Pocketbooks at Risk

Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.

A Health-Heavy State of the Union

President Joe Biden’s 2023 State of the Union address leaned heavily on health care issues. Biden took a victory lap for recent accomplishments like capping prescription drug costs for seniors on Medicare. He also urged Congress to make permanent the boosted premium subsidies under the Affordable Care Act, and he sparred with Republicans on threats to cut Social Security and Medicare. Also this week, both sides in the abortion debate are bracing for a court decision out of Texas that could, at least temporarily, make the abortion pill mifepristone illegal nationwide. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Kate Baicker of the University of Chicago about a possible middle ground in the effort to get universal health insurance coverage.

‘We Ain’t Gonna Get It’: Why Bernie Sanders Says His ‘Medicare for All’ Dream Must Wait

As he takes the reins of the Senate Health, Education, Labor & Pensions Committee, the independent from Vermont and implacable champion of “Medicare for All” maps out his strategy for negotiating with Republicans — and Big Pharma.

FDA Experts Are Still Puzzled Over Who Should Get Which Covid Shots and When

A single booster seems to prevent death and hospitalization in most people, but protection from the current vaccines wanes within months. FDA experts say they need to know more from the Centers for Disease Control and Prevention to decide the best long-term strategy.

Part I: The State of the Abortion Debate 50 Years After ‘Roe’

In Part I of this special two-part episode, Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Sarah Varney of KHN join KHN chief Washington correspondent Julie Rovner to discuss how the abortion debate has evolved since the Supreme Court overturned the nationwide right to abortion in 2022, and what might be the flashpoints for 2023. Also in this episode, Rovner interviews Elizabeth Nash of the Guttmacher Institute, about changing reproductive policies in the states.

GOP House Opens With Abortion Agenda

Leaders of the new Republican-led U.S. House kicked off their legislative agenda with two bills supported by anti-abortion groups. While neither is likely to become law, the move demonstrates how abortion will continue to be an issue in Washington. Meanwhile, as open enrollment for the Affordable Care Act nears its end in most states, the number of Americans covered by the plans hits a new high. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.